Multi-specific anti-HIV antibodies that neutralize almost all circulating HIV-1 viruses will be optimized to target persistent infection
New computational tool supports the engineering and development of cancer immunotherapies
Collaborations will explore using two novel types of biofunctional synthetic macromolecules of the polyphosphazene (PPZ) family for exciting and very different applications. In the first, PPZs will be developed for use as biocompatible and drug-releasing hydrophobic coatings for indwelling medical devices.
Tri-specific antibody targets and neutralizes 99.5% of HIV-1 virus strains
A team of researchers at IBBR, led by Dr. Yuxing Li, Associate Professor at the University of Maryland School of Medicine, Baltimore, and Principal Investigator at the Institute for Bioscience and Biotechnology Research (IBBR), Rockville, is showing how engineered multi-specific antibodies appear to be highly effective at preventing infection across a broad range of HIV-1 virus strains.
UMD researchers work to defend poplar trees – a promising resource for renewable and sustainable energy – from leaf rust and other diseases
Sarah Gao to Compete for Top Awards in Most Prestigious U.S. Science and Mathematics Competition for High School Seniors
Over $3M in Regeneron Science Talent Search Awards Will Be Distributed in 2018
New approaches hope to give researchers a glimpse into the cell’s “alert system” to fight tumors and viruses
The goal is to develop and test a “first-in-class multi-specific antibody“, which could offer dramatic advantages over current treatments for AIDS patients, help eliminate hidden reservoirs of HIV, and potentially deliver on the promise of a long-awaited HIV cure.
Renowned IBBR chemist to speak at the American Chemical Society National Meeting
(Rockville, MD, June 12, 2017) University of Maryland’s Institute for Bioscience and Biotechnology Research (IBBR) has been awarded a $6.0 million grant entitled, “Structure-Based Vaccine Design for Hepatitis C Virus”, to develop a novel prophylactic vaccine to prevent hepatitis C virus (HCV) infection. The grant is funded by the National Institutes of Health (NIH) and the research will take place over a five-year period.